Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Quick programming note: This newsletter will take a break for the Monday holiday, but we’ll be back in your inbox bright and early Tuesday. We’re lining up some great stories for next week, and don’t forget the STAT Summit is coming up in just five days.
The need-to-know this morning
- Bristol Myers Squibb said it would acquire Orbital Therapeutics for $1.5 billion, picking up experimental in vivo CAR-T therapies that could be used to treat autoimmune diseases.
Boston’s biotech supremacy is being challenged
Boston has long been the undisputed capital of the world’s life sciences industry, but that may be changing, writes The Boston Globe’s Shirley Leung.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
